Читать книгу Blood and Marrow Transplantation Long Term Management - Группа авторов - Страница 2

1  Cover

2  Title Page

3  Copyright Page

4  Foreword to the Second Edition

5  Foreword (from first edition)

6  List of Contributors

7  SECTION 1: Late effects concepts CHAPTER 1: Introduction to long‐term survivorship after hematopoietic cell transplantation Background Rapidly rising numbers of long‐term transplant survivors Long‐term issues in long‐term survivors Developing resources and a guide for long‐term survivors Declaration of commercial interest References CHAPTER 2: International Blood and Marrow Registries: trends on long‐term data collection Overview of the Role of Registries in HCT Overview of Late Effects Data Collection through Registries Future of Data Collection in Survivorship Center for International Blood and Marrow Transplant Research (CIBMTR) The Registry of the European Society for Blood and Marrow Transplantation (EBMT) Future plans Asia‐Pacific Blood and Marrow Transplant Group (APBMT) The Registry of the Eastern Mediterranean Blood and Marrow Transplantation Group (EMBMT) References CHAPTER 3: Long‐term follow‐up program and transplant clinic setup Introduction Concept of long‐term survivorship Late effects after HSCT Timing and transition to long‐term survivorship care The transition from pediatric to adult long‐term care Long‐term follow‐up program Long‐term follow‐up Clinic Long‐term transplant team and the annual LTFU visit Recommendation for screening and preventive practices Organizing a long‐term follow‐up clinic in resource‐limited countries References CHAPTER 4: Telemedicine in patient care of long‐term transplant survivors Introduction Principles of telehealth What we know about current models for hct survivorship Example of a LTFU telemedicine model Future directions References CHAPTER 5: Long‐term follow‐up calendar Introduction Survivorship care plan Schedule of the long‐term follow‐up visit Screening and preventive recommendations References CHAPTER 6: Late effects post‐allogeneic hematopoietic stem cell transplantation Introduction Identification of late effects Late effects Very late effects Future directions Summary References CHAPTER 7: Late effects post‐autologous hematopoietic stem cell transplantation Introduction Pulmonary Complications Cardiovascular Complications Secondary Malignancies Endocrine and Metabolic Complications Kidney Complications Infectious Complications Quality of Life and Psychosocial Effects Cognitive Dysfunction Special Considerations in Lymphoma and Myeloma Conclusion References CHAPTER 8: Long‐term follow‐up of children Introduction Common posttransplant screening and prevention guidelines Survivorship care plans References CHAPTER 9: Graft‐versus‐host disease and late effects after hematopoietic stem cell transplantation Introduction cGVHD and nonmalignant late effects Secondary Malignancies References CHAPTER 10: Screening and prevention guidelines for hematopoietic cell transplant survivors Introduction Published guidelines for screening and prevention of late complications in hsct survivors Non‐infectious late effects Infectious and immunologic Subsequent neoplasms Treatment summary and survivorship care plans Areas for future research References CHAPTER 11: Biology of survivorship after blood or marrow transplantation Introduction Anthracycline‐related heart failure Therapy‐related myeloid neoplasia Cognitive outcomes Conclusions References

8  SECTION 2: Specific late effects CHAPTER 12: Second malignancies Introduction Estimating the risk of second cancers Pathophysiology Risk factors for secondary malignancies Diagnosis, screening and prevention Management; Treatment and Recommendations References CHAPTER 13: Anti‐infective prophylaxis, immunization and prevention of late infectious complications Introduction Vaccination Prevention of bacterial infections Prevention of viral infections Prevention of fungal infections References CHAPTER 14: Seasonal respiratory viral infections Introduction Community Respiratory Virus Infections in HCT Recipients Respiratory viruses and alloimmune lung syndrome Diagnostic Evaluation Treatment Options Preventing exposure Preventing Disease and Progression to LRTI Future Considerations References CHAPTER 15: Monitoring and management of hepatitis B, C, and HIV infection before and after transplantation Hepatitis B Virus (HBV) Hepatitis C Virus (HCV) Human Immunodeficiency Virus (HIV) Acknowledgment References CHAPTER 16: Skin chronic GVHD Introduction cGVHD pathophyisiology Pathological findings in cutaneous cGVHD Clinical manifestations Clinical management Imaging and instrumental tools in skin cGVHD Systemic treatment Ancillary and topical treatment References CHAPTER 17: Ocular complications Introduction Ocular graft‐versus‐host disease Cataract formation Other non‐GVHD ocular complications Recommendations for the survivors / general practitioner References CHAPTER 18: Management of oral and dental complications Introduction Xerostomia and salivary gland hypofunction Oral graft‐versus‐host disease Jaw/bisphosphonate osteonecrosis Secondary malignancies Conclusions References CHAPTER 19: Thyroid disease: monitoring and management guidelines Introduction Hypothyroidism Hyperthyroidism Thyroid nodules Thyroid disorders and pregnancy post‐HSCT References CHAPTER 20: Pretransplant considerations in gender, reproductive, and sexual health Introduction Summary References CHAPTER 21: Posttransplant Considerations in Gender, Reproductive, and Sexual Health Introduction Genital chronic graft‐versus‐host disease Summary References CHAPTER 22: Fertility issues, fertility preservation, and pregnancy outcome in long‐term survivors Female fertility after HSCT Male fertility after HSCT Pregnancy after HSCT Maternal health during pregnancy following HSCT Fertility Prevention Counseling References CHAPTER 23: Sexual Dysfunction in Long‐Term Survivors Introduction Sexual Well‐Being and Sexual Distress Sexual Dysfunction Risk Factors Screening and Prevention Treatment Considerations for Sexual Minority Populations Recommendations for Practitioners Regarding SM Patients Recommendations for Practitioners Recommendations for Survivors References CHAPTER 24: Late non‐infectious pulmonary complications Introduction Early Non‐infectious Pulmonary Complications Posttransplant Lymphoproliferative Disorder (PTLD) Diagnostic considerations of non‐infectious pulmonary complications following HSCT Conclusion References CHAPTER 25: Cardiac and arterial complications Late cardiac dysfunction Arterial disease Disclosures References CHAPTER 26: Cardiovascular risk factors Introduction Dyslipidemia Hypertension Diabetes Other Endocrinopathies Metabolic syndrome Summary References CHAPTER 27: Gastrointestinal complications Introduction Pre‐existing gastrointestinal conditions Preconditioning‐related GI complications Acute and subacute complications Chronic complications Future directions Financial support Disclosures References CHAPTER 28: Hepatic Complications Introduction Initial evaluation Iron overload Chronic hepatic graft‐versus‐host disease (GVHD) Chronic hepatitis B (HBV) Chronic hepatitis C (HCV) Chronic hepatitis E (HEV) Non‐alcoholic fatty liver disease (NAFLD) Focal nodular hyperplasia (FNH) Nodular regenerative hyperplasia (NRH) Cirrhosis Hepatocellular carcinoma (HCC) References CHAPTER 29: Renal complications Introduction Acute kidney injury Chronic kidney disease Pathophysiology Thrombotic microangiopathy Proteinuria Podocytopathy Bk nephropathy End stage renal disease Strategies to prevent and mitigate kidney injury post HSCT References CHAPTER 30: Posttransplantation bone disease: prevalence, surveillance, prevention, and management Introduction Low Bone Mineral Density, Osteopenia and Osteoporosis Frequency/Cumulative Incidence Risk Factors Surveillance/Screening Prevention Treatment Other Agents Recommendation for the Survivor/General Practitioner Avascular Necrosis Screening/Surveillance Prevention Treatment Recommendations for the Survivor and General Practitioner References CHAPTER 31: Late neurologic complications Introduction Pathophysiology Frequency/cumulative incidence Risk Factors Clinical Entities Surveillance/ screening Prevention Recommendation for the survivors / general practitioner References CHAPTER 32: Neurocognitive dysfunction Introduction Definition and critical domains of neurocognitive dysfunction Risk factors and correlates Biomarkers as potential mechanisms Neurocognitive dysfunction in adult patients with HCT Neurocognitive dysfunction in special populations Assessment Interventions Concluding remarks References CHAPTER 33: Psychological Distress Introduction Late survivorship Screening for distress Treatment Recommendations for the survivors/general practitioner References CHAPTER 34: Evaluation and management of fatigue in survivors of allogeneic hematopoietic stem cell transplantation Introduction Pathophysiology of Fatigue in HSCT Survivors Pharmacologic interventions Non‐pharmacologic interventions Complementary and integrative therapies Summary References CHAPTER 35: Social Issues Introduction Social Factors Associated with HCT Access and Outcomes Influence of HCT on Social Well‐being Relationship Between Social and Psychological Factors Instruments to Assess Social Risks Conclusion References CHAPTER 36: Health‐related quality of life in adult and pediatric survivors Introduction Quality of life Clinical Features of Treatment with Allogeneic HSCT Health‐related Quality of Life Physical Function Adults Psychological function Social and role functioning Benefit‐finding and post‐traumatic growth Healthy lifestyle and health‐promoting behaviors Application to practice Interventions Summary References

9  SECTION 3: Supportive care and patients reported outcomes CHAPTER 37: Immunosuppressive agents and monitoring in long‐term survivors GVHD Prophylaxis Agents: GVHD Treatment Agents References CHAPTER 38: Nutritional support and nutritional supplementation Introduction (Definition; subgroups) Pathophysiology Frequency/cumulative incidence Risk factors Surveillance/ screening Prevention Treatment Recommendation for the survivors / general practitioner References CHAPTER 39: Daily routines and healthy lifestyle guidelines Background Education Infection Prevention Compliance with Scheduled Follow Up Health Maintenance Screenings Community/Home Support Summary References CHAPTER 40: Prevalent psychosocial adjustment issues and solutions Introduction The patient and their support system: coping with stress in the long‐term care setting The patient and caregiver: facing intimacy issues Other quality of life issues for the stem‐cell transplant patient Conclusion References CHAPTER 41: Complementary and alternative medicine in HSCT Introduction Natural products in HCT recipients Mind and body practices in HCT recipients Other complementary and alternative medicine Safety of complementary and alternative medicine Approach to CAM discussions Future directions References CHAPTER 42: Impact of adherence in outcome of long‐term survivors Introduction Adherence Non‐Adherence Non‐intentional and intentional non‐adherence HSCT a risk factor for non‐adherence Recommendation for healthcare providers Future research Conclusion References CHAPTER 43: Prominent role of allied health professionals Introduction Immunizations References CHAPTER 44: Patient reported outcomes Introduction Basic concepts about PROs Perceived health status Physical function and symptom burden post‐HCT Psychological aspects post‐HCT Social aspects post‐HCT Behavioral aspects post‐HCT PROs and GVHD PROs as predictors of HCT survival Conclusion References CHAPTER 45: Caregivers of long‐term survivors Introduction Frequency/cumulative incidence Risk factors Surveillance/ screening Recommendation for the survivors/caregivers/general practitioner References CHAPTER 46: Patient’s perspective Lilian Living a normal Life Hello Cancer So, here we go! Staging the Cancer Staging and Sarah Cannon Clinical Trials Lymphomaniac Remission PET Scan and What's Next? Vanderbilt Hematology and Stem Cell Clinic Transplant Day Now for the Fun Part: Four Months of Treatment Going Home Returning to Everyday Life Twenty‐Three and Me / Ancestory.Com Medical Surprises and Life for the past 10 Years Blood Clots More Post‐Transplant Medical Surprises Colonoscopy Colon Cancer Surgery Tumor Board Wake Up Call Radiation Treatments The Puppy from Hell The Move to Florida The last of the Cancer‐Related Episodes The Continuation of the Story but not the End So Much to be Thankful For

10  APPENDIX 1: Commonly used transplant‐related medications in long‐term survivors References

11  APPENDIX 2: The eGVHD App References

12  Index

13  End User License Agreement